In bladder urothelial carcinoma, ERBB2 mutations have been associated with favorable response to platinum-based neoadjuvant chemotherapy. However, this association has not been reported in upper tract urothelial carcinoma (UTUC). We describe an excellent response to cisplatin-based chemotherapy in metastatic UTUC with an ERBB2 mutation. Our patient is a 54-year-old female with metastatic UTUC who received systemic cisplatin and gemcitabine. Post-chemotherapy imaging demonstrated decreased size of pyelocaliceal mass and decreased retroperitoneal adenopathy compared to initial imaging. Surgical pathology from consolidative resection showed 3mm residual renal tumor and no viable lymph node disease. Genomic testing demonstrated an ERBB2 gain of function mutation.
Urology. 2023 Dec 03 [Epub ahead of print]
Kristin Weiss, Obafunbi Abimbola, Kelsey Miller, William Y Kim, Tracy L Rose, Marc A Bjurlin, Kathryn H Gessner
University of North Carolina School of Medicine, Chapel Hill, NC., Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC., Department of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC., Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC; Department of Pharmacology, University of North Carolina at Chapel Hill, NC; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, NC; Department of Genetics, University of North Carolina at Chapel Hill, NC., Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC; Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, NC., Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC., Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: .